Statins have been found to reduce the production of proinflammatory cytokines, particularly IL-17 and IL-21, in SLE patients by inhibiting the Rho-associated, coiled-coil-containing protein kinase (ROCK) pathway [69]. This evidence concerns the gene IL21 and systemic lupus erythematosus.